ASAlmer M. van der Sloot

Almer M. van der Sloot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Almer M. van der Sloot has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation

    by Roger Palou, Almer M. van der Sloot, Aline A. Fiebig, Megan T. Zangara, Naseer Sangwan, María Sánchez-Osuna, Bushra Ilyas, Haley Zubyk, Michael Cook, Gerard D. Wright, et al.

    Protein-based pharmaceuticals, such as engineered antibodies, form a major drug class of steadily increasing market share. However, these biologic medicines are costly to manufacture, are subject to strict supply chain and storage constraints, and often require invasive administration routes. Engineered microbes that secrete bioactive products directly within the microbiome milieu may mitigate these challenges. Here, we describe a cell microfactory platform based on the probiotic yeast Saccharomyces boulardii for the production of nanobody biologics in the gastrointestinal (GI) tract. High-level secretion of nanobodies by S. boulardii was achieved by optimizing promoters, secretion signals and antibody formats. In mice, oral gavage of S. boulardii allowed efficient and transient colonization of the colonic compartment, and in situ production of a therapeutic nanobody directed against tumor necrosis factor (TNF). In a mouse model of chemical-induced colitis, GI-delivery of anti-murine TNF nanobody via live S. boulardii improved both survival and disease severity without causing overt perturbation of microbiome composition. These results position S. boulardii as a synthetic biotic platform for the in situ production and delivery of protein-based therapeutics to the GI tract.


  • Open Access

    A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture

    by Jasmin Coulombe-Huntington, Thierry Bertomeu, Caroline Huard, Andrew Chatr-Aryamontri, Daniel J. St-Cyr, María Sánchez-Osuna, David Papadopoli, Karine Normandin, Mohammadjavad Paydar, Shannon McLaughlan, et al.

    To probe drug mechanism of action (MOA) and interrogate the genetic architecture of human cells, we carried out isogenic genome-wide CRISPR/Cas9 knockout screens against 310 diverse drugs, bioactive compounds, and stress conditions. Stringent statistical correction for gene knockout fitness defects yielded a large-scale matrix of >12,000 high confidence chemical-genetic interactions (CGIs). This dataset revealed many previously unappreciated off-target effects for well-characterized compounds and novel MOAs for uncharacterized compounds. The CGI matrix uncovered dense genetic modules that yielded new biological insights into phospholipidosis, mitotic regulation, metabolism, the DNA damage response, and mTOR signaling. The dataset allowed identification of multi-drug sensitization and resistance mechanisms, inference of gene function, elaboration of cross-process connectivity, evaluation of the cell type specificity of CGIs, prediction of chemical synergism, and extensive annotation of understudied genes. This resource provides a map of the genetic landscape in human cells and a framework to help guide drug discovery.


  • Open Access

    A Saccharomyces boulardii synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation

    by Roger Palou, Almer M. van der Sloot, Aline A. Fiebig, Megan T. Zangara, Naseer Sangwan, María Sánchez Osuna, Bushra Ilyas, Haley Zubyk, Michael Cook, Gerard D. Wright, et al.

    Protein-based pharmaceuticals, such as engineered antibodies, form a major drug class of steadily increasing market share. However, these biologic medicines are costly to manufacture, are subject to strict supply chain and storage constraints and often require invasive administration routes. Engineered microbes that secrete bioactive products directly within the microbiome milieu may mitigate these challenges. Here, we describe a cell microfactory platform based on the probiotic yeast Saccharomyces boulardii for the production of nanobody biologics in the gastrointestinal (GI) tract. High-level secretion of nanobodies by S. boulardii was achieved by optimizing promoters, secretion signals, and antibody formats. In mice, oral gavage of S. boulardii allowed efficient and transient colonization of the colonic compartment and in situ production of a therapeutic nanobody directed against tumor necrosis factor (TNF). In a mouse model of chemical-induced colitis, GI-delivery of anti-mTNF nanobody via live S. boulardii improved both survival and disease severity without causing overt perturbation of microbiome composition. These results position S. boulardii as a synthetic biotic platform for the in situ production and delivery of protein-based therapeutics to the GI tract.

  • Open Access

    Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzyme–ubiquitin complex

    by Daniel St-Cyr, Derek F. Ceccarelli, Stephen Orlicky, Almer M. van der Sloot, Xiaojing Tang, Susan Kelso, Susan Moore, Clint James, Ganna Posternak, Jasmin Coulombe-Huntington, et al.

    Small-molecule stabilization of weak ubiquitin-enzyme interactions to selectively target the ubiquitin-proteasome system.


  • Open Access

    Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

    by Fred D. Mast, Arti T. Navare, Almer M. van der Sloot, Jasmin Coulombe-Huntington, Michael P. Rout, Nitin S. Baliga, Alexis Kaushansky, Brian T. Chait, Alan Aderem, Charles M. Rice, et al.

    With the rapid global spread of SARS-CoV-2, we have become acutely aware of the inadequacies of our ability to respond to viral epidemics. Although disrupting the viral life cycle is critical for limiting viral spread and disease, it has proven challenging to develop targeted and selective therapeutics. Synthetic lethality offers a promising but largely unexploited strategy against infectious viral disease; as viruses infect cells, they abnormally alter the cell state, unwittingly exposing new vulnerabilities in the infected cell. Therefore, we propose that effective therapies can be developed to selectively target the virally reconfigured host cell networks that accompany altered cellular states to cripple the host cell that has been converted into a virus factory, thus disrupting the viral life cycle.


  • Open Access

    Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development

    by Samuel Jacques, Almer M. van der Sloot, Caroline C. Huard, Jasmin Coulombe-Huntington, Sarah Tsao, Sylvain Tollis, Thierry Bertomeu, Elizabeth J. Culp, Daniel Pallant, Michael A Cook, et al.

    Systematic genetic interaction profiles can reveal the mechanisms-of-action of bioactive compounds. The imipridone ONC201, which is currently in cancer clinical trials, has been ascribed a variety of different targets. To investigate the genetic dependencies of imipridone action, we screened a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout library in the presence of either ONC201 or its more potent analog ONC212. Loss of the mitochondrial matrix protease CLPP or the mitochondrial intermediate peptidase MIPEP conferred strong resistance to both compounds. Biochemical and surrogate genetic assays showed that impridones directly activate CLPP and that MIPEP is necessary for proteolytic maturation of CLPP into a catalytically competent form. Quantitative proteomic analysis of cells treated with ONC212 revealed degradation of many mitochondrial as well as nonmitochondrial proteins. Prompted by the conservation of ClpP from bacteria to humans, we found that the imipridones also activate ClpP from Escherichia coli, Bacillus subtilis, and Staphylococcus aureus in biochemical and genetic assays. ONC212 and acyldepsipeptide-4 (ADEP4), a known activator of bacterial ClpP, caused similar proteome-wide degradation profiles in S. aureus. ONC212 suppressed the proliferation of a number of Gram-positive (S. aureus, B. subtilis, and Enterococcus faecium) and Gram-negative species (E. coli and Neisseria gonorrhoeae). Moreover, ONC212 enhanced the ability of rifampin to eradicate antibiotic-tolerant S. aureus persister cells. These results reveal the genetic dependencies of imipridone action in human cells and identify the imipridone scaffold as a new entry point for antibiotic development.


  • Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants

    by Cheng Xu, Daniele Cassatella, Almer M. van der Sloot, Richard Quinton, Michael Hauschild, Christian De Geyter, Christa Flück, Katrin Feller, Deborah Bartholdi, Attila Nemeth, et al.


  • At Long Last, a C-Terminal Bookend for the Ubiquitin Code

    by Andrew Chatr-Aryamontri, Almer van der Sloot, Mike Tyers


  • Open Access

    Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity

    by Laura A. Carleton, Reka Chakravarthy, Almer M. van der Sloot, Katarzyna Mnich, Luis Serrano, Afshin Samali, Adrienne M. Gorman